EMA recommends approval of Mekinist for treatment of melanoma The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorization for Mekinist for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Mekinist is the first cancer treatment that selectively targets the MEK protein kinase. The applicant for Mekinist is GlaxoSmithKline. The CHMP opinion on Mekinist will now be sent to the European Commission for adoption of a decision on an EU-wide marketing-authorization.
GlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.